Yahoo
NasdaqGM - Delayed Quote USD

MediWound Ltd. (MDWD)

13.29 +0.08 (+0.61%)
At close: September 4 at 4:00:01 PM EDT
13.29 0.00 (0.00%)
After hours: September 4 at 7:30:03 PM EDT
Trade MDWD on Coinbase
Chart Range Bar
Loading chart for MDWD
  • Previous Close 13.21
  • Open 13.13
  • Bid 10.22 x 200
  • Ask 18.25 x 200
  • Day's Range 13.03 - 13.41
  • 52 Week Range 12.52 - 20.30
  • Volume 86,155
  • Avg. Volume 84,503
  • Market Cap (intraday) 171.578M
  • Beta (5Y Monthly) 0.14
  • PE Ratio (TTM) --
  • EPS (TTM) -2.16
  • Earnings Date Nov 19, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 29.83

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

www.mediwound.com

121

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MDWD
28.01%
S&P 500 (^GSPC)
12.75%

1-Year Return

MDWD
20.70%
S&P 500 (^GSPC)
18.71%

3-Year Return

MDWD
62.47%
S&P 500 (^GSPC)
70.93%

5-Year Return

MDWD
50.17%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 1.48M
Earnings -2.95M
Profit Margin -200.14%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

-10M
-5M
0
5M
-300.0%
-200.0%
-100.0%

Analyst Insights

View More

Analyst Price Targets

22.00
29.83 Average
13.29 Current
36.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/14/2026
Analyst Oppenheimer
Rating Action Maintains
Rating Outperform
Price Action Lowers
Price Target 32 -> 30

Statistics

View More

Valuation Measures

Annual
As of 9/3/2026
  • Market Cap

    171.06M

  • Enterprise Value

    144.33M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    14.07

  • Price/Book (mrq)

    4.80

  • Enterprise Value/Revenue

    12.17

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -170.10%

  • Return on Assets (ttm)

    -28.59%

  • Return on Equity (ttm)

    -72.37%

  • Revenue (ttm)

    11.86M

  • Net Income Avi to Common (ttm)

    -20.18M

  • Diluted EPS (ttm)

    -2.16

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    35.34M

  • Total Debt/Equity (mrq)

    24.14%

  • Levered Free Cash Flow (ttm)

    -29.05M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

13.29 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: